Minerva Neurosciences, Inc.
NERV
$4.73
-$0.01-0.21%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 285.72% | -51.60% | -- | -66.38% | -67.31% |
| Gross Profit | -285.72% | 51.60% | -- | 66.38% | 67.31% |
| SG&A Expenses | 349.40% | 10.58% | -22.58% | -14.11% | 1.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 327.16% | 10.16% | -34.86% | -46.25% | -41.59% |
| Operating Income | -327.16% | -10.16% | 34.86% | 46.25% | 41.59% |
| Income Before Tax | -3,241.44% | -6,540.16% | -112.19% | 60.42% | 56.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3,241.44% | -6,540.16% | -112.19% | 60.42% | 56.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3,241.44% | -6,540.16% | -112.19% | 60.42% | 56.20% |
| EBIT | -327.16% | -10.16% | 34.86% | 46.25% | 41.59% |
| EBITDA | -327.28% | -10.16% | 34.87% | 46.26% | 41.60% |
| EPS Basic | -476.16% | -4,420.61% | -112.19% | 60.42% | 56.21% |
| Normalized Basic EPS | -476.12% | -4,419.95% | -112.19% | 60.42% | 56.20% |
| EPS Diluted | -476.16% | -4,420.61% | -112.21% | 60.42% | 56.21% |
| Normalized Diluted EPS | -476.12% | -4,419.95% | -112.19% | 60.42% | 56.20% |
| Average Basic Shares Outstanding | 480.00% | 46.89% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 480.00% | 46.89% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |